For upto date info please visit: mythreyelab.org
Singh P, Jenkins LM, Horst B, Alers V, Pradhan S, Kaur P, Srivastava T, Hempel N, Győrffy B, Broude EV, Lee NY, Mythreye K. Inhibin is a novel paracrine factor for tumor angiogenesis and metastasis. Cancer Res. 2018 Mar 13. pii: canres.2316.2017. doi: 10.1158/0008-5472.CAN-17-2316. [Epub ahead of print]
Jenkins LM, Horst B, Lancaster CL, Mythreye K.Dually modified transmembrane proteoglycans in development and disease.Cytokine Growth Factor Rev. 2017 Dec 22. pii: S1359-6101(17)30193-4. doi: 10.1016/j.cytogfr.2017.12.003. [Epub ahead of print] Review.
Kim YS, Gupta Vallur P, Phaëton R, Mythreye K, Hempel N. Insights into the Dichotomous Regulation of SOD2 in Cancer.Antioxidants (Basel). 2017 Nov 3;6(4). pii: E86. doi: 10.3390/antiox6040086
Varadaraj A, Jenkins LM, Singh P, Chanda A, Snider J, Lee NY, Amsalem-Zafran AR, Ehrlich M, Henis YI, Mythreye K. TGF-β triggers rapid fibrillogenesis via a novel TβRII dependent fibronectin trafficking mechanism. Mol Biol Cell. 2017 Mar 15. pii: mbc.E16-08-0601. doi: 10.1091/mbc.E16-08-0601
Jenkins LM, Singh P, Varadaraj A, Lee NY, Shah S, Flores HV, O'Connell K, Mythreye K. Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem. 2016 Dec 2;291(49):25716-25728. Epub 2016 Oct 26
Kumar S, Pan CC, Shah N, Wheeler SE, Hoyt KR, Hempel N, Mythreye K, Lee NY. Activation of Mitofusin2 by Smad2-RIN1 Complex during Mitochondrial Fusion. Mol Cell. 2016 May 19;62(4):520-31. doi: 10.1016/j.molcel.2016.04.010. Epub 2016 May 12
A. Varadaraj, P.Patel, A.Serrao, T.Bandyopadhay, N.Y.Lee, A.A.Jazaeri,Z. Huang, S. K Murphy and K. Mythreye. Epigenetic regulation of GDF2 suppresses anoikis in ovarian and breast epithelia. Neoplasia.2015 Nov;17(11):826-38. doi: 10.1016/j.neo.2015.11.003.
Pan CC, Kumar S, Shah N, Bloodworth JC, Hawinkels LJ, Mythreye K, Hoyt DG, Lee NY. Endoglin Regulation of Smad2 Function Mediates Beclin1 Expression and Endothelial Autophagy. J Biol Chem. 2015 Jun 12;290(24):14884-92. doi: 10.1074/jbc.M114.630178. Epub 2015 Apr 30.
Lukas D. Osborne, George Z. Li, Tam How, E. Tim O'Brien III, G. C. Blobe, Richard Superfine and K. Mythreye. TGF-β regulates LARG and GEF-H1 during EMT to impact stiffening response to force and cell invasion. Mol. Biol. Cell August 20, 2014 mbc.E14-05-1015
Pan CC, Kumar S, Shah N, Hoyt DG, Hawinkels LJ, Mythreye K, Lee NY. Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis. J Biol Chem. 2014 Jul 28. pii: jbc.M114.578609. [Epub ahead of print] PubMed PMID: 25070888.
Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest. 2013 Nov 1;123(11):4786-98. PubMed PMID: 24216509; PubMed Central PMCID: PMC3809791.
Oh SY, Knelson EH, Blobe GC, Mythreye K. The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J. 2013 Aug 15;454(1):79-89. doi: 10.1042/BJ20121701. PubMed PMID: 23750457; PubMed Central PMCID: PMC4082962.
Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells. Oncogene. 2013 Mar 14;32(11):1416-27. doi: 10.1038/onc.2012.157. Epub 2012 May 7. PubMed PMID: 22562249; PubMed Central PMCID: PMC3835656.
Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J. 2012 Oct 3;31(19):3885-900. doi: 10.1038/emboj.2012.246. Epub 2012 Aug 31. PubMed PMID: 22940691; PubMed Central PMCID: PMC3463850.
Pan CC, Bloodworth JC, Mythreye K, Lee NY. Endoglin inhibits ERK-induced c-Myc and cyclin D1 expression to impede endothelial cell proliferation. Biochem Biophys Res Commun. 2012 Aug 3;424(3):620-3. doi: 10.1016/j.bbrc.2012.06.163. Epub 2012 Jul 10. PubMed PMID: 22789855; PubMed Central PMCID: PMC3412906.
Swaminathan V, Mythreye K, O'Brien ET, Berchuck A, Blobe GC, Superfine R. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res. 2011 Aug 1;71(15):5075-80. doi: 10.1158/0008-5472.CAN-11-0247. Epub 2011 Jun 3. PubMed PMID: 21642375; PubMed Central PMCID: PMC3220953.
Lambert KE, Huang H, Mythreye K, Blobe GC. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 2011 May;22(9):1463-72. doi: 10.1091/mbc.E10-11-0877. Epub 2011 Mar 16. PubMed PMID: 21411633; PubMed Central PMCID: PMC3084669.
Mythreye K, Blobe GC. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal. 2009 Nov;21(11):1548-58. doi: 10.1016/j.cellsig.2009.05.001. Epub 2009 May 8. Review. PubMed PMID: 19427900; PubMed Central PMCID: PMC2735586.
Mythreye K, Blobe GC. The type III TGFbeta receptor regulates directional migration: new tricks for an old dog. Cell Cycle. 2009 Oct 1;8(19):3069-70. Epub 2009 Oct 8. PubMed PMID: 19755845.
Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8221-6. doi: 10.1073/pnas.0812879106. Epub 2009 May 1. PubMed PMID: 19416857; PubMed Central PMCID: PMC2688894.